Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 91

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 91
---
’s net cash of $185 million as of June 27, 2025 and divided the results by the diluted common stock share count of STAAR calculated using the treasury stock method, based on equity information as of July 30, 2025, as provided by STAAR management. This analysis indicated an approximate implied per share equity value reference range for STAAR of $16.35 to $23.80, as compared to the closing share price of the STAAR common stock as of August 1, 2025, of $17.76, and the Merger Consideration of $28.00. Selected Precedent Transactions Analysis Using publicly available information, Citi performed a selected precedent transactions analysis of STAAR in which Citi reviewed financial data relating to the following seven selected transactions that Citi considered generally relevant for purposes of analysis, which are collectively referred to as the “selected transactions”:

| Announcement Date |     | Acquiror                      |     | Target                       |
| 03/24/2025        |     | Alcon Inc.                    |     | LENSAR, Inc.                 |
| 06/18/2024        |     | Boston Scientific Corporation |     | Silk Road Medical, Inc.      |
| 02/09/2023        |     | Abbott Laboratories           |     | Cardiovascular Systems, Inc. |
| 01/12/2021        |     | STERIS plc                    |     | Cantel Medical Corp.         |
| 12/18/2020        |     | Koninklijke Philips N.V.      |     | BioTelemetry, Inc.           |
| 11/04/2019        |     | Stryker Corporation           |     | Wright Medical Group N.V.    |
| 08/30/2018        |     | Stryker Corporation           |     | K2M Group Holdings, Inc.     |

Although none of the target companies in the selected transactions are directly comparable to STAAR and none of the selected transactions are directly comparable to the transactions contemplated by the Merger Agreement, the selected transactions were chosen because they involved businesses with financial, operational or business characteristics that, in Citi’s view, based on its professional judgment and experience, made them sufficiently comparable to STAAR and/or the transaction contemplated by the Merger Agreement or otherwise relevant for purposes of analysis. For each of the selected transactions, Citi reviewed, among other information, enterprise value as a multiple of the applicable target company